Guarini Kathryn sold $360K of REGN
Guarini Kathryn sold 400 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $900.00 ($0.36M total) on 2026-10-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest relative to Regeneron's market cap and likely will not move the stock significantly.
Market read
A routine insider sale with limited market impact; traders may note the transaction but no immediate action is required.
What to watch
The 10b5-1 plan indicates the sale was pre‑planned, reducing the informational value of the transaction.
Background
SEC Form 4 filing discloses insider transactions; directors often use 10b5-1 plans to execute pre‑arranged trades.
Ticker impact
Director Kathryn Guarini sold 400 shares of Regeneron for $360,000 via a 10b5-1 plan, reducing her stake to 603 shares.
likely slight pressure as the market prices in the insider sell
A director sold a modest amount of stock under a pre‑arranged plan; such sales typically signal neutral to mildly negative sentiment.
Market effects
Minimal impact on the biotech sector; insider sales are routine.
No significant regional effect.
Limited to Regeneron investors.
Counterpoint
The sale could be unrelated to company fundamentals and may be purely portfolio rebalancing.
Key entities
- CompanyRegeneron Pharmaceuticals, Inc.
Biopharmaceutical company whose director sold shares.
- PersonKathryn Guarini
Director of Regeneron who executed the sale.



